Thirty rejection episodes occurred after a mean period of 14.3 days after transplantation. Ninety-one patients had induction treatment with either antithymocyte globulin (ATG) or interleukin 2 receptor antibodies (IL2 Rab). The drugs included cyclosporine, mycophenolate, sirolimus, azathioprine, and prednisolone in these patients. There was no significant difference in ARE among the different drug protocols (30.7 % –35.2 % ). Subjects with 4 or more HLA mismatches displayed more ARE (40.3 % ) compared with those with 3 or less (23 % ). Subjects with ATN or DGF immediately posttransplantation had a higher incidence of ARE (39.2 % ) than those without them (26.3 % ). Deceased donor recipients had a higher episode of ARE (45.1 % ) compared with live related donor recipients (25 % ). On stratifying the known risk factors for ARE, subjects with no risk factors had the least (22.2 % ) ARE compared with those with one (32.5 % ) or two (47.6 % ) risk factors. Subjects who failed to achieve adequate cyclosporine (C2) levels showed significantly higher rates of ARE (86.9 % ) than those with adequate or higher levels (8.6 % ).
Higher HLA mismatches, DGF, deceased donor, and failure to achieve adequate cyclosporine levels were observed to be major risk factors for the development of ARE.